Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes
A Randomised, Parallel-group, Open-labelled, Multinational Trial Comparing the Efficacy and Safety of Insulin Detemir (Levemir®) Versus Human Insulin (NPH Insulin), Used in Combination With Insulin Aspart as Bolus Insulin, in the Treatment of Pregnant Women With Type 1 Diabetes
Sponsor: Novo Nordisk A/S
This PHASE3 trial investigates Diabetes and Diabetes Mellitus, Type 1 and is currently completed. Novo Nordisk A/S leads this study, which shows 8 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
May 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — May 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
May 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Aarhus N, Denmark , Alcoy, Spain , Alicante, Spain , Amiens, France , Angers, France , Barcelona, Spain , Belfast, United Kingdom , Bergen, Norway , Birmingham, United Kingdom and 76 more locations